Jason C. O'COnnor has a total of 163 co-authors. Here are the top co-authors by number of shared publications:

  • Laney Redus

    Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900

    9 shared publications
  • Jennifer M. Parrott

    Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900

    7 shared publications
  • Danielle Santana-Coelho

    Department of Pharmacology, UT Health San Antonio, TX, United States; Audie L. Murphy VA Hospital, South Texas Veterans Health System, San Antonio, TX, United States

    4 shared publications
  • Robert Dantzer

    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

    4 shared publications
  • Danielle Santana-Coelho

    Laboratorio de Farmacologia Molecular, Instituto de Ciencias Biologicas (ICB), Universidade Federal do Para (UFPA), Belem, Brazil

    3 shared publications
  • Keith Wayne Kelley

    Department of Pathology, College of Medicine and Department of Animal Sciences, College of ACES, University of Illinois at Urbana-Champaign, 212 Edward R. Madigan Laboratory, 1201 West Gregory Drive, Urbana, IL 61801, USA

    3 shared publications

Latest Publications

  • KMO deletion preserves non-associative learning and SVZ neurogenesis in aging mice

    by Miguel A. de la Flor, Natalia Kuhn-Sandoval, Danielle Santana-Coelho, Damian Lozano, Samuel J. Harrison, Morgan C. Bucknor, Mustafa N. Mithaiwala, Jason C. O’COnnor, Erzsebet Kokovay

  • Open Access

    Analysis of Gene, Environment, and Sex Interaction in the Development of Autistic-like Phenotype in Mice

    by Danielle Santana-Coelho, Grace Porter, Juan Morales, Jason C. O’Connor

    Autism Spectrum Disorder (ASD) is a developmental disorder that manifests a broad variability of phenotypes. The underlying factors contributing to the diverse presentation of autistic phenotypes remain poorly understood. Studies have shown that environmental and genetic factors could contribute to ASD. Additionally, there is a sex bias in the disorder, where the prevalence in males is higher than in females. But it is still unknown how exposure to similar risk factors can lead to different phenotypes. The three-hit theory states that the vulnerability of an individual to develop ASD is modulated by the interplay between genetic predisposition, sex, and environmental insults. To better understand this phenomenon, we investigated whether an environmental insult, via maternal immune activation (MIA) during pregnancy could influence the development of the autistic-like phenotype in a genetically predisposed mouse strain, contactin-associated protein-like 2 (CNTNAP2) knockout. CNTNAP2 knockout, sex, and maternal immune activation had significantly additive effects on repetitive/stereotyped and social behavior in the offspring, while working memory and sensory gating were not affected by hits. These results indicate that genetics, sex, and environment interact to influence autistic-like phenotypes in a behavior-specific manner.

  • Open Access

    The role of the kynurenine pathway in the pathophysiology of autism-like phenotype induced by maternal inflammation in male mice

    by Danielle Santana-Coelho, Rafael dos Santos de Bessa, Rodrigo Neves Romcy-Pereira, Miguel A. de la Flor, Jason C. O'COnnor


  • Open Access

    Losing the Filter: How Kynurenine Pathway Dysregulation Impairs Habituation

    by Miguel A. de la Flor, Jason C. O’connor

    Habituation is a fundamental form of non-associative learning that allows organisms to filter out repetitive, non-salient stimuli but declines with age. While the kynurenine pathway (KP) of tryptophan metabolism is implicated in psychiatric and neurodegenerative diseases, its role in age-related habituation deficits has been overlooked. This review proposes a systems-level framework suggesting that age-related, chronic inflammation KP dysregulation is a key driver of habituation deficits. We present evidence showing that neurotoxic metabolites from the kynurenine-3-monooxygenase (KMO)-dependent branch drive a self-reinforcing cycle of oxidative stress, excitotoxicity, and glial reactivity that destabilizes the neural circuits required for habituation. This framework redefines KP modulation as context dependent: metabolites such as kynurenic acid (KYNA), which can be disruptive when elevated in youth, may become compensatory under the oxidative load of aging. Our findings that genetic KMO deletion preserves habituation in aged and old mice provide the first direct in vivo evidence supporting this model. We propose that inhibiting the KMO branch preserves habituation not by simply altering metabolite levels but by restoring homeostatic balance across neuroimmune, redox, and plasticity networks. KMO thus emerges as a critical node for maintaining cognitive resilience, offering a therapeutic target for preserving brain function during aging.


  • Open Access

    Branched-Chain Amino Acids Combined with Exercise Improves Physical Function and Quality of Life in Older Adults: Results from a Pilot Randomized Controlled Trial

    by Ronna Robbins, Jason C. O’connor, Tiffany M. Cortes, Monica C. Serra

    This pilot, randomized, double-blind, placebo-controlled trial investigated the effects of branched-chain amino acids (BCAAs)—provided in a 2:1:1 ratio of leucine:isoleucine:valine—combined with exercise on fatigue, physical performance, and quality of life in older adults. Twenty participants (63% female; BMI: 35 ± 2 kg/m2; age: 70.5 ± 1.2 years) were randomized to 8 weeks of either exercise + BCAAs (100 mg/kg body weight/d) or exercise + placebo. The program included moderate aerobic and resistance training three times weekly. Physical function was assessed using handgrip strength, chair stands, gait speed, VO2 max, and a 400 m walk. Psychological health was evaluated using the CES-D, Fatigue Assessment Scale (FAS), Insomnia Severity Index (ISI), and global pain, fatigue, and quality of life using a visual analog scale (VAS). Significant group x time interactions were found for handgrip strength (p = 0.03), chair stands (p < 0.01), and 400 m walk time (p < 0.01). Compared to exercise + placebo, exercise + BCAAs showed greater improvements in strength, mobility, and endurance, along with reductions in fatigue (−45% vs. +92%) and depressive symptoms (−29% vs. +5%). Time effects were also observed for ISI (−30%), FAS (−21%), and VAS quality of life (16%) following exercise + BCAA supplementation. These preliminary results suggest that BCAAs combined with exercise may be an effective way to improve physical performance and reduce fatigue and depressive symptoms in older adults.


  • Open Access

    Dysregulated Neuroimmune and Anhedonia-like Behavioral Response Following Peripheral Immune Challenge in Mice Carrying the Val66Met Brain-Derived Neurotrophic Factor Polymorphism

    by Mustafa N. Mithaiwala, Allison M. Dugan, Miguel A. de la Flor, Sandeep K. Subramanian, Ashley Acheson, Jason C. O’connor

    Dysregulated inflammatory processes contribute to depression, and gene–environment interactions may influence an individual’s risk and resilience. Reduced brain-derived neurotrophic factor (BDNF) expression increases susceptibility for developing depressive symptoms, and the Val66Met (rs6265) single-nucleotide polymorphism (SNP) on the BDNF gene is linked to mood disorders. However, whether Val66Met confers increased vulnerability to inflammation-induced depressive tendencies is unknown. Here, we tested the hypothesis that the Val66Met SNP increases vulnerability to inflammation-induced depressive symptoms in a mouse model of lipopolysaccharide (LPS)-induced depression-like behavior. Behavior and neuroinflammation, following a 24 h LPS challenge, were measured in mice expressing the human BDNF Val66Met gene variant or Val66Val littermates (control). The Val66Met genotype did not affect the peripheral inflammatory response, acute neuroinflammation, or the acute sickness behavior response. Val66Met mice exhibited anhedonia-like behavioral responses following LPS challenge, and we found increased mRNA expression of IL-1β and TNFα in the cerebrum compared to controls. The mRNA expression of IL-1β and TNFα in the hippocampus and the nucleus accumbens of Val66Met mice was increased following LPS, and a significant genotype × LPS interaction was detected for CD68 expression in the nucleus accumbens. In summary, these data suggest that immune activation in Val66Met mice increased susceptibility to anhedonic behavior and dysregulated negative regulation of inflammation.

  • Open Access

    Dysregulated Neuroimmune and Anhedonia-like Behavioral Response Following Peripheral Immune Challenge in Mice Carrying the Val66Met Brain Derived Neurotrophic Factor Polymorphism

    by Mustafa N Mithaiwala, Allison M Garrison, Sandeep K Subramanian, Ashley Acheson, Jason C O'Connor

    Dysregulated inflammatory processes contribute to depression, and gene-environment interactions may influence an individual’s risk and resilience. Reduced brain-derived neurotrophic factor (BDNF) expression increases susceptibility for developing depressive symptoms and the Val66Met (rs6265) single nucleotide polymorphism (SNP) on the BDNF gene is linked to mood disorders. However, whether Val66Met confers increased vulnerability to inflammation-induced depressive tendencies is unknown. Here, we tested the hypothesis - Val66Met SNP increases vulnerability to inflammation-induced depressive symptoms in a mouse model of lipopolysaccharide (LPS)-induced depression-like behavior. Behavior and neuroinflammation, following a 24hr LPS challenge, were measured in mice expressing human BDNF Val66Met gene variant or Val66Val littermates (control). The Val66Met genotype did not affect the peripheral inflammatory response, acute neuroinflammation, or the acute sickness behavior response. Val66Met mice exhibited anhedonia-like behavioral response following LPS challenge, and we found increased mRNA expression of IL-1β and TNFα in the cerebrum compared to controls. The mRNA expression of IL-1β and TNFα in the hippocampus and the nucleus accumbens of Val66Met mice were increased following LPS, and an interaction was detected for CD68 expression in the nucleus accumbens. In summary, these data suggest immune activation in Val66Met mice increased susceptibility to anhedonic behavior and dysregulated negative regulation of inflammation.

  • Open Access

    Quinolinic acid potentially links kidney injury to brain toxicity

    by Afaf Saliba, Subrata Debnath, Ian Tamayo, Hak Joo Lee, Nagarjunachary Ragi, Falguni Das, Richard Montellano, Jana Tumova, Meyer Maddox, Esmeralda Trevino, et al.

    Kidney dysfunction often leads to neurological impairment, yet the complex kidney-brain relationship remains elusive. We employed spatial and bulk metabolomics to investigate a mouse model of rapid kidney failure induced by mouse double minute 2 ( Mdm2 ) conditional deletion in the kidney tubules to interrogate kidney and brain metabolism. Pathway enrichment analysis of a focused plasma metabolomics panel pinpointed tryptophan metabolism as the most altered pathway with kidney failure. Spatial metabolomics showed toxic tryptophan metabolites in the kidneys and brains, revealing a connection between advanced kidney disease and accelerated kynurenine degradation. In particular, the excitotoxic metabolite quinolinic acid was localized in ependymal cells in the setting of kidney failure. These findings were associated with brain inflammation and cell death. Separate mouse models of ischemia-induced acute kidney injury and adenine-induced chronic kidney disease also exhibited systemic inflammation and accumulating toxic tryptophan metabolites. Patients with advanced chronic kidney disease (stage 3b-4 and stage 5) similarly demonstrated elevated plasma kynurenine metabolites, and quinolinic acid was uniquely correlated with fatigue and reduced quality of life. Overall, our study identifies the kynurenine pathway as a bridge between kidney decline, systemic inflammation, and brain toxicity, offering potential avenues for diagnosis and treatment of neurological issues in kidney disease.


  • Open Access

    Meningeal dendritic cells drive neuropathic pain through elevation of the kynurenine metabolic pathway in mice

    by Alexandre G. Maganin, Guilherme R. Souza, Miriam D. Fonseca, Alexandre H. Lopes, Rafaela M. Guimarães, André Dagostin, Nerry T. Cecilio, Atlante S. Mendes, William A. Gonçalves, Conceição E.A. Silva, et al.

    Neuropathic pain is one of the most important clinical consequences of injury to the somatosensory system. Nevertheless, the critical pathophysiological mechanisms involved in neuropathic pain development are poorly understood. In this study, we found that neuropathic pain is abrogated when the kynurenine metabolic pathway (KYNPATH) initiated by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is ablated pharmacologically or genetically. Mechanistically, it was found that IDO1-expressing dendritic cells (DCs) accumulated in the dorsal root leptomeninges and led to an increase in kynurenine levels in the spinal cord. In the spinal cord, kynurenine was metabolized by kynurenine-3-monooxygenase–expressing astrocytes into the pronociceptive metabolite 3-hydroxykynurenine. Ultimately, 3-hydroxyanthranilate 3,4-dioxygenase–derived quinolinic acid formed in the final step of the canonical KYNPATH was also involved in neuropathic pain development through the activation of the glutamatergic N-methyl-D-aspartate receptor. In conclusion, these data revealed a role for DCs driving neuropathic pain development through elevation of the KYNPATH. This paradigm offers potential new targets for drug development against this type of chronic pain.


  • Open Access

    Kynurenine Metabolism as a Mechanism to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors Following Resistance Training

    by Ronna N. Robbins, Jessica L. Kelleher, Priyathama Vellanki, Jason C. O’connor, Jennifer S. Mascaro, Joe R. Nocera, Monica C. Serra

    This pilot examines whether resistance training (RT) can induce changes in kynurenine (KYN) metabolism, which may contribute to improved physical function in breast cancer survivors (BCSs). Thirty-six BCSs (63.2 ± 1.1 years) underwent assessments of physical function and visual analog scale (100 cm) fatigue and quality of life before and after 12 weeks of RT (N = 22) or non-exercise control (CBCT©: Cognitively Based Compassion Training, N = 10). Blood was collected before and after interventions for assessment of KYN, kynurenic acid (KYNA), and peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α). At baseline, the women were moderately fatigued (mean score: 46 cm) and at risk of poor functional mobility. A group*time interaction was observed for all measures of strength with improvements (~25–35%) following RT (p’s < 0.01), but not CBCT. Time effects were observed for fatigue (−36%) and quality of life (5%) (p’s < 0.01), where both groups improved in a similar manner. A group*time interaction was observed for KYN (p = 0.02) and PGC-1α (p < 0.05), with KYN decreasing and PGC-1α increasing following RT and the opposite following CBCT. These changes resulted in KYN/KYNA decreasing 34% post-RT, but increasing 21% following CBCT. These data support RT as a therapeutic intervention to counteract the long-term side effect of fatigue and physical dysfunction in BCSs. Additionally, the results suggest that this effect may be mediated through the activation of PGC-1α leading to alterations in KYN metabolism.